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Summary Since the treatment of postmenopausal breast cancer patients with aminoglutethimide caused
hypothyroidism with an unexpectedly high frequency previous treatment was suspected to contribute to
hypofunction of the thyroid. Serum thyrotropin, triiodothyronine and free thyroxine index were compared
between breast cancer patients who had undergone irradiation of regional lymph nodes and non-irradiated
breast cancer patients, as well as patients having endometrial or colorectal carcinoma. Subclinical and clinical
primary hypothyroidism was significantly more frequent in breast cancer patients who had previously received
irradiation on supraclavicular lymph nodes comprising a minor part of the thyroid. Testing for the presence
of autoantibodies against thyroid tissue components gave no evidence for radiation-induced autoimmune
thyroiditis. Drugs suppressing thyroid hormone synthesis like aminoglutethimide may frequently cause
myxedema in such irradiated women, especially at postmenopausal age.
When we studied the merits of aminoglutethimide
for the treatment of metastatic breast cancer in
postmenopausal women in a phase II clinical trial
we were confronted with an incidence of manifest
myxedema in 25% and of subclinical hypo-
thyroidism, still compensated by a rise of serum
thyrotropin (TSH) in 78% of the patients after 8
weeks (Bruning et al., 1984). This relatively high
incidence of diminished thyroid function seemed to
be related to a relatively high frequency of elevated
pretreatment TSH levels in our study population.
In this report we present evidence that post-
operative irradiation of supraclavicular lymph
nodes in postmenopausal breast cancer patients
may frequently lead to subclinical thyroid
dysfunction although the irradiation comprises only
a minor part of the thyroid. This finding explains
why a drug like aminoglutethimide by a further
decrement of thyroid hormone synthesis (Studer et
al., 1970; Gower, 1974) may often lead to
myxedema in such patients.
Subjects and methods
Thyroid function parameters including serum TSH,
thyroxine (T4), triiodothyronine (T3), and T3-resin
uptake (T3RU) were determined in 5 groups of
postmenopausal women treated in the Antoni van
Leeuwenhoek Hospital of the Netherlands Cancer
Institute from December 1964 to January 1984.
Patients treated surgically for primary breast cancer
who underwent postoperative irradiation of regional
lymph nodes because of an increased risk of
metastasis belonged to one of two groups. Group I
consisted of 100 women irradiated on the nodes
along the ipsilateral internal mammary artery
because of a medial localization of the primary
tumour or when axillary lymph node metastasis was
present. Group II consisted of 100 women who had
undergone breast amputation and subsequently
received irradiation to the chest wall and regional
lymph nodes, including the ipsilateral internal
mammary, infraclavicular and supraclavicular node
chains, because of unfavourable prognostic signs
such as incomplete axillary dissection or the
involvement of infraclavicular nodes. The cumu-
lative dose applied to these areas varied from 40Gy
in 3 weeks to 50Gy in 5 weeks (Fletcher et al.,
1980). It seemed reasonable to assume that in both
groups a minor part of the thyroid could have
received direct irradiation. The fields of irradiation
are shown in Figure 1. The field of irradiation on
the internal mammary nodes was modified in 1980.
The resulting subpopulations IA (before modifi-
cation) and IB (after modification) were studied
together since the possible involvement of the
thyroid was judged to be similar. Patients belonging
to Groups I, II and III received endocrine
treatment other than aminoglutethimide or hypo-
physectomy, chemotherapy or no further treatment
from the time of irradiation of regional lymph
nodes until blood sampling for the estimation of
thyroid function. For comparison 3 control groups
of patients who had not received any irradiation of
the thyroid were studied: 50 women on admission
for surgery of primary breast cancer without
irradiation (group III), 50 women on admission for
endometrial carcinoma (group IV) and 50 women
on admission for colorectal carcinoma (group V).
The age distribution of the 5 groups is given in
Table I. The hormone assays were done in serum
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Figure 1 Fields of irradiation in groups IA, IB and II.
Table I Age distribution (years).
Group n Mean age s.d.
I 100 57.3 13.4
II 100 62.3 12.2
III 50 73.7 9.0
IV 50 69.3 6.9
V 50 68.0 8.3
individual T4 by T3RU values yielded free
thyroxine indexes (FTI).
Autoantibodies directed against thyroid antigens
were determined by Coons' immunofluorescence
technique: after incubation of frozen sections of
human thyroid with patient's 1/10 diluted serum
fluoresceine isothiocyanate-conjugated sheep anti-
serum against human immunoglobulin was added.
Statistical analysis included analysis of variance
and the Student-Newman-Keuls multiple com-
parison analysis (Keuls, 1952).
samples stored during maximally 30 months at
-20'C until analysis. Blood samples were taken
after irradiation at 1 to 156 (mean 43.2) months in
group I and 3-240 (mean 49.6) months in group II,
and before treatment in groups III, IV and V. TSH
was determined by a double antibody radio-
immunoassay using a specific polyclonal rabbit
antiserum from Immuno Nuclear Corporation as
first antibody and a Sac-cellg donkey anti-rabbit
antiserum from Wellcome as second antibody. T4,
T3 and T3RU were measured by radioimmunoassay
using kits from Diagnostic Products Corporation
(Los Angeles, California). Multiplication of the
Results
The observed prevalence of abnormal thyroid
function parameters is summarized in Table II.
After logarithmic transformation of the TSH-values
because of their skewed distribution multiple
comparison analysis revealed that groups I and II,
which had received postoperative irradiation
involving a part of the thyroid with almost
certainty, contained significantly more patients with
elevated TSH concentrations than the control
groups III, IV and V (P=0.00001) (Figure 2).
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Table II Prevalence of abnormal thyroid function para-
meters.
Group I II III IV V
TSH>3.0,pUmla 10/100 25/100 1/50 6/50 1/50
T4<5.3jig lOOmlb 2/10 3/25 0/1 0/6 0/1
T3RU <24%b 4/10 14/25 1/1 0/6 0/1
FTI < 1.27b 2/10 4/25 0/6 0/6 0/1
aFor all patients.
bFor patients with elevated TSH.
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Figure 2 Logarithmic
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normal.
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controls than group I.
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Since we were interested in primary thyroid
dysfunction, T4, T3 and T3RU were measured only
in sera with elevated TSH concentrations. The
results are shown in Table III. As can be seen from
Tables II and III, more hypothyroid values were
found in groups I and II than in the controls,
group II containing most overtly hypothyroid cases.
To exclude the possibility that age distribution
might bias the results all ages and log TSH values
were compared in a polynomial regression analysis.
The same was done for the non-irradiated breast
cancer patients (group III) separately. No signi-
ficant correlation was observed in either analysis.
Testing of the presence of autoantibodies against
human thyroid components was done in sera with
elevated TSH levels. In only a few patients
immunofluorescence was judged as positive for
antibodies against thyroglobulin or microsomal
antigens or both. The results did not suggest any
consistent relationship between detectability of
antibodies and previous irradiation or between the
presence of immunofluoresence and the degree to
which TSH was elevated.
Discussion
The unexpected high frequency of thyroid
* hypofunction in postmenopausal breast cancer
patients treated with AG, a drug known to impair
- thyronine synthesis (Studer et al., 1970; Gower,
1974), led us to consider the antecedents of our
4 5 patients more closely. As it appeared that a great
proportion of the women showed elevated serum
TSH levels already before treatment with AG, two
serum TSH- possibilities had to be studied. The treatment of
e regarded as breast cancer patients previous to the endocrine
therapy of metastatic disease could cause subclinical
or overt primary hypothyroidism, or post-
menopausal breast cancer itself could be associated
ore from the with diminished thyroid function. Since post-
operative radiotherapy involving the thyroid seemed
Table III Thyroid function parameters.a
Group I II III IV V Normal range
N 10 25 1 6 1
TSHyUml 8.03+7.08 6.97+5.33 3.60 7.02+4.02 3.80 0.7-3.0
T4MG100ml-' 7.21+2.35 8.51+3.64 8.80 6.27+0.53 7.80 5.3-11.3
T3RU% 24.51±1.49 23.07+4.16 23.80 27.98+1.71 25.70 24-34
FTI 1.76+0.53 1.85+0.59 2.09 1.75+0.19 2.00 1.27-3.84
T3ngml ' 1.13+0.14 1.29+0.26 0.8-2.1
aMean +s.d. only if TSH was elevated further tests were done.
M
U1)
0
-0.5
i
A:
ILr o662 P. BRUNING et al.
the most likely factor influencing its function, we
selected breast cancer patients with and without
postoperative irradiation of regional lymph nodes.
A highly significant difference of occurrence of
compensatory serum TSH levels was observed
between the irradiated and non-irradiated breast
cancer patients. Because of the fields of irradiation
the patients of group II were expected to have
greater chances of thyroid damage than the patients
of group I. The observed occurrence rate of
elevated TSH levels in group II being highest would
fit this expectation. It seems unlikely that the
increased occurrence of diminished thyroid function
was due to previous chemotherapy or endocrine
treatment other than with aminoglutethimide. It is
unlikely also that breast cancer itself is associated
with primary hypothyroidism, as no significant
differences were found between the non-irradiated
breast cancer group III and the control patients
with endometrial or colorectal cancer (group IV
and V). Although an increased incidence of hypo-
thyroidism has been reported in breast cancer
patients (Mittra & Hayward, 1974; Rose & Davies,
1978; Thomas et al., 1983) other workers have not
observed such an association (Schottenfield, 1968;
Hedley et al., 1981). Radiotherapy involving the
thyroid region for head and neck cancer (Shafer et
al., 1975; Posner et al., 1984) or Hodgkin's disease
(Schimpff et al., 1980; Smith et al., 1981; Peden et
al., 1982) has been reported to be followed by an
increased incidence of mostly subclinical hypo-
thyroidism. In these cases the whole thyroid was
generally irradiated with cumulative doses ranging
from 40 to 70Gy. In our breast cancer patients the
postoperative irradiation could only comprise a
minor fraction of the total thyroid gland, i.e. the
lower part of the ipsilateral lobe and the isthmus.
Yet this appeared to be sufficient to cause a
significantly increased occurrence of elevated TSH
levels. The much more sensitive TSH rise after
administration of thyrotropin releasing hormone
would probably have revealed an even greater
occurrence ofdiminished thyroid function.
The present data do not indicate a consistent
pattern of autoantibodies against thyroid which
might explain the results after damaging only part
of the thyroid by radiation directly. This is in
agreement with observation by others (Schimpff et
al., 1980; Holten, 1983).
Treatment with 131J jas been demonstrated to be
associated with the development of thyroid anti-
bodies, i.e. predominantly microsomal antibodies
(Lundell & Johnson, 1973). However, charac-
teristics of the thyroid irradiation by 131J are quite
different from those of external radiotherapy.
Moreover patients treated with 131J invariably had
thyroid disease, which more frequently entails the
generation of autoantibodies. Thyroid antibodies
occur in apparently healthy individuals, especially
females and more frequently with increasing age.
The sparse occurrence of thyroid antibodies in our
patients, therefore, is no good evidence for an
autoimmune reaction to radiation damage to the
thyroid. Other tests may be necessary to reveal the
possible induction of autoimmune thyroiditis.
Direct radiation damage, be it to only a minor part
of the thyroid may just add to the progressive
decrement of function which is often present in
postmenopausal women. In the same way amino-
glutethimide may contribute to a condition which
becomes clinically manifest as myxedema.
The drug's action is known to involve
competitive inhibition at the mitochondrial P450
cytochrome level. In this way it interferes with
hydroxylation steps required for the formation of
various steroid hormones such as cortisol and
aldosterone or the precursors of estrone and
estradiol (Santen et al., 1982). Hydroxylation steps
normally needed for iodination involved in the
synthesis of thyroid hormones may also be
hampered to an extent which leads to clinically
manifest hypothyroidism.
In our previous study (Bruning et al., 1984) we
observed that 17 out of 32 patients entered into a
phase II clinical trial of aminoglutethimide 1000mg
plus hydrocortisone 40mg daily for advanced
postmenopausal breast cancer had elevated serum
TSH levels before treatment. Of these 17 patients
11 had received irradiation on supraclavicular
lymph nodes in the past. Only 7 of the 15 patients
with normal pretreatment levels of TSH had been
treated similarly. After 8 weeks of amino-
glutethimide therapy 5 additional patients had
elevated TSH values, one of them without previous
irradiation. All but 2 patients with elevated pre-
treatment values of serum TSH showed a further
increase at 8 weeks, 7 of them developing clinically
manifest hypothyroidism with decreased free
thyroxine index values. The difference in occurrence
of hypothyroidism which was observed by Santen
(1980) as sporadic and by ourselves as rather
frequent, can readily be explained by the infrequent
use of postoperative irradiation of supraclavicular
lymph nodes in the American breast cancer patients
(R.J. Santen, personal communication). Clinicians
treating elderly women with cytochrome P450
inhibiting drugs like aminoglutethimide should be
aware of the possible deterioration of thyroid
function especially when the organ has been
irradiated in the past.HYPOTHYROIDISM AFTER REGIONAL IRRADIATION FOR BREAST CANCER 663
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